City of Hope researchers recently reported on the successful treatment of a patient with recurrent multifocal glioblastoma using CAR-T therapy
Thanks Ray, nice article. When I wrote up Biopharma several days ago, I tried (probably inadequately) to express how amazing it is to get any results at all in treating recurrent glioblastoma. The excitement that the people at City of Hope expressed about getting a remission in one patient! and the fact that NEJM, a very top of the line medical journal, accepted the case report as newsworthy, makes it clear how amazing ZioPharma’s results are, with a study of 17 of these patients, and over 70% surviving at 12 months at the favored dosage.
And ZioParma announced today that they have definitely been accepted by the FDA to go on to a stage 3 study.
Thanks again,
Saul